Healthcare provider and patient perspectives on the implementation of pharmacogenetic-guided treatment in routine clinical practice

被引:0
|
作者
Kaur, Gurveer [1 ]
Nwabufo, Chukwunonso K. [1 ,2 ,3 ]
机构
[1] OneDrug Inc, Toronto, ON, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Dept Pharmaceut Sci, Toronto, ON, Canada
[3] Hosp Sick Children, Program Translat Med, Toronto, ON, Canada
来源
PHARMACOGENETICS AND GENOMICS | 2024年 / 34卷 / 07期
基金
加拿大健康研究院;
关键词
adverse drug reactions; healthcare provider; implementation; patient; personalized medicine; pharmacogenetics; pharmacogenetic testing device; point-of-care; PHARMACISTS PERCEPTION; CONTEXT; EXPERIENCES; SUPPORT; POINT;
D O I
10.1097/FPC.0000000000000541
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
ObjectiveThis study aims to understand patient and healthcare provider perspectives on the integration and application of pharmacogenetics (PGx) testing in routine clinical practice.MethodsTwo anonymous online surveys were distributed globally for healthcare providers and patients respectively on the Qualtrics platform (version 3.24). The surveys were distributed through social platforms, email, and posters with QR codes from 27 October 2023 to 7 March 2024. The surveys evaluated participant familiarity with PGx, previous experience with PGx testing, perceived implementation challenges, and opinions on point-of-care (PoC) PGx testing devices.ResultsThis study collected 78 responses from healthcare providers and 98 responses from patients. The results revealed that 64% of healthcare providers had some level of familiarity with PGx, however, PGx testing in clinical practice was low. The primary challenges identified by healthcare providers included limited access to testing and lack of knowledge on PGx test interpretation. In contrast, 52% of patient respondents were aware of PGx testing, with a significant association between awareness and positive opinions toward PGx. Both healthcare providers and patients recognized the value of PoC PGx testing devices, with 98% of healthcare providers and 71% of patients believing PoC devices would improve the accessibility and implementation of PGx testing. Comparative analysis revealed a statistically significant difference in PGx awareness between healthcare providers and patients, with providers being more informed.ConclusionImproved PGx awareness, training, clinical guidelines, and PoC PGx testing devices may help promote the implementation of PGx-guided treatments in routine clinical practice.
引用
收藏
页码:236 / 245
页数:10
相关论文
共 50 条
  • [1] Pharmacogenetic-Guided Treatment of Depression: Real-World Clinical Applications, Challenges, and Perspectives
    Zanardi, Raffaella
    Manfredi, Elena
    Montrasio, Cristina
    Colombo, Cristina
    Serretti, Alessandro
    Fabbri, Chiara
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (03) : 573 - 581
  • [2] PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
    Killam, S.
    Davie, M.
    Wall, D.
    Brown, K.
    Aagaard, K.
    Claw, K.
    Woodahl, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S117 - S117
  • [3] Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin
    Verhoef, Talitha I.
    Schalekamp, Tom
    Redekop, William K.
    de Boer, Anthonius
    Maitland-van der Zee, Anke-Hilse
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2010, 10 (04) : 375 - 378
  • [4] PERSPECTIVES ON PHARMACOGENETIC-GUIDED TOBACCO CESSATION IN AN AMERICAN INDIAN POPULATION
    Killam, S.
    Davie, M.
    Wall, D.
    Brown, K.
    Aagaard, K.
    Claw, K.
    Woodahl, E.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 : S9 - S9
  • [5] Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
    Michael J. Sorich
    Michael D. Wiese
    Rebekah L. O’Shea
    Brita Pekarsky
    PharmacoEconomics, 2013, 31 : 377 - 391
  • [6] Review of the Cost Effectiveness of Pharmacogenetic-Guided Treatment of Hypercholesterolaemia
    Sorich, Michael J.
    Wiese, Michael D.
    O'Shea, Rebekah L.
    Pekarsky, Brita
    PHARMACOECONOMICS, 2013, 31 (05) : 377 - 391
  • [7] Conducting routine fatigue assessments for use in clinical oncology practice: patient and provider perspectives
    Davis, Kimberly M.
    Lai, Jin-Shei
    Hahn, Elizabeth A.
    Cella, David
    SUPPORTIVE CARE IN CANCER, 2008, 16 (04) : 379 - 386
  • [8] Conducting routine fatigue assessments for use in clinical oncology practice: patient and provider perspectives
    Kimberly M. Davis
    Jin-Shei Lai
    Elizabeth A. Hahn
    David Cella
    Supportive Care in Cancer, 2008, 16 : 379 - 386
  • [9] Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    M Verbelen
    M E Weale
    C M Lewis
    The Pharmacogenomics Journal, 2017, 17 : 395 - 402
  • [10] Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
    Verbelen, M.
    Weale, M. E.
    Lewis, C. M.
    PHARMACOGENOMICS JOURNAL, 2017, 17 (05): : 395 - 402